<DOC>
	<DOC>NCT01488110</DOC>
	<brief_summary>The purpose of this study is to evaluate the efficacy of a novel therapy for treatment of migraine, pain reduction and relief of associated symptoms during ongoing migraine attacks, and presence of a preventive effect two months post treatment. Another purpose is to investigate if and how this treatment affects manifestations of the autonomic nervous system activity.</brief_summary>
	<brief_title>Investigation of Efficacy and Outcome of a New Medical Device for Treatment of Migraine</brief_title>
	<detailed_description />
	<mesh_term>Migraine Disorders</mesh_term>
	<criteria>Female or male subjects, in otherwise good health, 20 to 55 years of age Subjects who meet the ICHD2 (2nd Edition of The International Headache Classification) criteria for migraine headache Subjects with a minimum of 1 migraine attack per month Attack duration of 4 to 72 hours Normal attack intensity of at least 4 on a 010 VASscale Completed heart surgery Cardiovascular diseases Vascular damages on neck vessels Diseases other than migraine of the CNS Severe disease of vital body organs Severe psychiatric disorders More than 6 migraine attacks per month</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>June 2013</verification_date>
</DOC>